Can a diabetes drug stop prediabetes in its tracks?
NCT ID NCT05426525
First seen Jan 24, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This study tests whether empagliflozin, a drug used for type 2 diabetes, can improve blood sugar control in adults with prediabetes who are overweight or obese. Sixty participants will receive either the drug or a placebo for 13 weeks. Researchers will measure how the body handles sugar and burns fat to see if the drug can prevent progression to diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oregon State University
Corvallis, Oregon, 97331, United States
Conditions
Explore the condition pages connected to this study.